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ABSTRACT  1 
Aims: To evaluate the glycaemic control of combination therapy with basal insulin and 2 
liraglutide, and to explore the factors predictive of efficacy in patients with type 2 diabetes 3 
when switched from longstanding basal-bolus insulin therapy. 4 
Methods: We studied 41 patients who switched from basal-bolus insulin therapy of more 5 
than 3 years to basal insulin/liraglutide combination therapy. Glycaemic control was 6 
evaluated at 6 months after switching therapy and used to subdivide the patients into 7 
good-responders (HbA1c <7.0% or 1.0% decrease) and poor-responders (the rest of 8 
participants). To evaluate the glucose-dependent insulin/glucagon responses without/with 9 
liraglutide, a 75-g oral glucose tolerance test (OGTT) was performed twice, before 10 
(1st-OGTT) and 2-days after (2nd-OGTT) liraglutide administration.  11 
Results: Twenty-eight patients (68.3%) were identified as good-responders. No 12 
differences were found in baseline characteristics including insulin/glucagon responses 13 
during 1st-OGTT between the groups. 2nd-OGTT revealed that paradoxical 14 
hyperglucagonemia were significantly improved in both groups, but significant increases 15 
in insulin secretory response were observed only in good-responders. Logistic regression 16 
analyses revealed that the improvement of the insulin-response during 2nd-OGTT 17 
compared to that during 1st-OGTT is associated with the good-responder. 18 
4 
Conclusions: Enhancement of glucose-dependent insulin-response under liraglutide 1 
administration is a potential predictor of long-term glycaemic control after switching the 2 
therapies.  3 
 4 
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1. INTRODUCTION 1 
The typical clinical course of type 2 diabetes is characterized by progressive 2 
deterioration of the pancreatic β-cells that synthesize and secret insulin [1], resulting in 3 
worsening glycaemic control and sequential addition of anti-diabetic agents, including 4 
insulin, over time. The basal-bolus insulin regimen, in which patients take basal insulin 5 
once a day and rapid-acting insulin before each meal, is typically the final step in the 6 
therapeutic progression [2]. Even with intensive basal-bolus insulin therapy, however, in 7 
most cases it is difficult to achieve excellent glycaemic control clinically due to the high 8 
risks of hypoglycaemia and weight gain by inadequate insulin dosage.   9 
 The glucagon-like peptide-1 (GLP-1) receptor agonist has recently garnered 10 
attention as a breakthrough drug for patients with type 2 diabetes. The GLP-1 receptor 11 
agonist (GLP-1RA) has several potential benefits because it enhances insulin secretion 12 
glucose-dependently and concurrently ameliorates insulin resistance through weight 13 
reduction [3]. It has also been shown that GLP-1RA ameliorates post-prandial 14 
hyperglycaemia by suppressing glucagon secretion and delaying gastric emptying [3]. Eng 15 
and colleagues reported their findings from a systematic review and meta-analysis of 16 
evidence about the combination of basal insulin and GLP-1RA in type 2 diabetes. 17 
Compared with basal-bolus insulin therapy, treatment with GLP-1RA plus basal insulin 18 
6 
gave a clinically insignificant reduction in HbA1c, but with a lower relative risk of 1 
hypoglycaemia and a reduction in body weight [4]. As a result, this combination therapy is 2 
becoming increasingly common in the treatment of type 2 diabetes [5, 6]. GLP-1 receptor 3 
agonists are subdivided into short-acting compounds and long-acting compounds such as 4 
liraglutide. The long-acting GLP-1 receptor agonists have a lower incidence of adverse 5 
effects such as nausea and vomiting [7]. It is possible that a regimen combining a 6 
once-a-day injection of basal insulin with long-acting GLP-1RA would be an effective 7 
alternative to a basal-bolus insulin regimen with less gastrointestinal discomfort and less 8 
treatment burden.  9 
Several pilot studies in Japan have retrospectively shown that the response to 10 
GLP-1RA is associated with fasting or postprandial serum C-peptide levels or the 11 
C-peptide response to glucagon-challenge test in type 2 diabetes patients at the initiation 12 
of GLP-1RA without any concomitant insulin regimen [8-10]. These facts suggest that the 13 
individual’s responses to mono-injectable therapy of GLP-1RA rely on the residual β-cell 14 
function and that GLP-1RA might be effective to some degree for type 2 diabetes patients 15 
with reduced β-cell function when combined with basal insulin. Moreover, Germain and 16 
colleagues recently reported that a higher insulin sensitivity calculated by insulin tolerance 17 
test was another predictive marker for a mono-injectable therapy of liraglutide with OADs. 18 
7 
[11]. 1 
Very recently, Usui and colleagues demonstrated a retrospective study that the 2 
residual β-cell function indicated by the fasting C-peptide index was a predictive marker 3 
for the achievement of HbA1c <7.0% by combination therapy with basal insulin and 4 
liraglutide 1 year after switching from therapy with basal-bolus or basal insulin with 5 
OADs [12]. However, it remains unclear what kind of patients would most benefit from 6 
such a switch in therapy to a combination with basal insulin and GLP-1RA, especially 7 
among those who had received longstanding basal-bolus insulin therapy, that is the final 8 
step in the therapeutic progression in type 2 diabetes.  9 
In this study, we prospectively examined what determines the long-term efficacy of 10 
replacing bolus insulin with liraglutide in patients with type 2 diabetes treated with 11 
longstanding basal-bolus insulin therapy from the standpoint of the responses of β- and 12 
α-cells to GLP-1 stimulation. 13 
 14 
 15 
2. MATERIALS AND METHODS 16 
2.1. Participants 17 
Eligible type 2 diabetic patients were Japanese adults over 20 years of age who had 18 
8 
been under treatment with basal-bolus insulin therapy (herein BBT) for more than 3 years 1 
prior to being enrolled in this study. None of the participants had previously been treated 2 
with GLP-1RA. Patients were excluded if they had type 1 diabetes, severe renal disorder 3 
with an estimated glomerular filtration rate < 20 mL/min/1.73m2 and/or current dialysis, 4 
liver disease, chronic pancreatitis, history of gastrointestinal surgery or pancreatomy, 5 
alcohol abuse, diabetogenic medications including steroids, malignancy or pregnancy.  6 
 7 
2.2 Study design 8 
This was a single-centre, open-label, prospective cohort study in patients with type 9 
2 diabetes at Nagasaki University Hospital from April 2015 to September 2017 10 
(UMIN-CTR, UMIN000021693). The study protocol is shown in Fig. 1. 11 
The participants were admitted to Nagasaki University Hospital and achieved a 12 
good level of glycaemic control (fasting glucose levels, 80-120 mg/dL) by using 13 
intensified basal-bolus insulin while discontinuing all OADs, excluding metformin and 14 
pioglitazone. Liraglutide was started at 0.3 mg before breakfast and increased to 0.6 mg on 15 
the following day. The 75-g oral glucose tolerance test (OGTT) was used to estimate β- 16 
and α-cell functions before starting liraglutide (1st-OGTT). The OGTT was re-performed 17 
two days after starting liraglutide (2nd-OGTT) to evaluate the responses of β- and α-cells 18 
9 
by GLP-1 stimulation. Liraglutide was injected 30 minutes prior to starting the 2nd-OGTT. 1 
Both OGTTs were carried out under the condition of overnight fasting. Basal insulin and 2 
OADs including metformin and pioglitazone were held until the preceding day in each 3 
OGTT.  4 
After the 2nd-OGTT, the patients were withdrawn from bolus insulin and switched 5 
to the simultaneous injections of basal insulin and GLP-1RA (liraglutide) combination 6 
therapy (herein BGT) in the morning. Clinicians were permitted to change the doses of 7 
basal insulin, liraglutide and metformin in the outpatient setting to keep the fasting glucose 8 
levels under 120 mg/dL. The maximum doses of liraglutide and metformin permitted in 9 
Japan were 0.9 mg and 2250 mg per day, respectively. We discontinued liraglutide and 10 
excluded the participants from the study if we observed potential adverse events of 11 
liraglutide, such as severe hypoglycaemia requiring hospitalization, unbearable nausea or 12 
vomiting, stroke, myocardial infarction, malignancy and any other diseases that needed 13 
hospitalization. The glycaemic status of patients was evaluated at 6 months after switching 14 
therapy and the patients were sub-divided into good-responders, defined as those with 15 
HbA1c <7.0% or a decrease in HbA1c of more than 1.0%, and poor-responders, defined as 16 
those meeting neither criterion.   17 
The patients were all encouraged to practice appropriate diet and exercise and 18 
10 
educated in regard to this practice throughout the study period. As a nutrition therapy, the 1 
participants were instructed to intake a 25-30 kcal/kg/day of their ideal body weight 2 
depending on the amount of activity of daily living, comprised of carbohydrates at 50-60% 3 
of total calories. Written informed consent was obtained from all participants. The study 4 
was approved by the ethical committee of Nagasaki University Hospital (approval no. 5 
15012676) and carried out in accordance with the declaration of Helsinki.  6 
 7 
2.3. Laboratory measurements 8 
As described above in the study design and in Fig 1, OGTTs were carried out 9 
twice (1st- and 2nd-OGTT) using a 75-g glucose formulation, Trelan-G75 (AY Pharma, 10 
Tokyo, Japan). The levels of plasma glucose (mg/dL), serum insulin (μU/mL), serum 11 
C-peptide (ng/mL) and plasma glucagon (pg/mL) were measured at fasting (0 min) and at 12 
30, 60, 120 min after ingestion of glucose load on each OGTT. The fasting levels of serum 13 
proinsulin (pmol/L) were also measured on both 1st- and 2nd-OGTT.  14 
The levels of serum insulin and C-peptide were measured by using an ECLusys 15 
kit (Roche, Basel, Switzerland). The insulin assay cannot detect any insulin analogues but 16 
measure human insulin specifically. Blood samplings for plasma glucagon were performed 17 
using BD P800 tubes (BD, Franklin Lakes, NJ, USA). Plasma glucagon was measured as 18 
11 
previously described [13], by using a recently produced sandwich enzyme-linked 1 
immunosorbent assay (ELISA) kit (Mercodia, Uppsala, Sweden) with almost no 2 
cross-reactivities against other glucagon-related peptides [14, 15]. Proinsulin was 3 
measured by using a sandwich ELISA kit (Mercodia, Uppsala, Sweden). Other laboratory 4 
measurements including plasma glucose were measured by standard assays.  5 
C-peptide index was calculated as 100 × C-peptide (ng/mL)/glucose (mg/dL) as 6 
an estimated residual β-cell function. The values of the changes from baseline (0 min) to 7 
120 min during the OGTTs in the levels of glucose, insulin, C-peptide and glucagon were 8 
indicated as ΔGlucose120min, ΔInsulin120min, ΔC-peptide120min and ΔGlucagon120min, 9 
respectively. Three-day means of blood glucose levels just before discharge from the 10 
hospital were shown as the profile of mean blood glucose levels just after switching from 11 
BBT to BGT.  12 
 13 
2.4. Statistical analysis 14 
Repeated-measures analysis of variance was used to test differences between 15 
good-responders and poor-responders. A paired t-test was used to test differences in each 16 
time point between 1st-OGTT and 2nd-OGTT in a single group. Logistic regression 17 
analyses were performed to determine the long-term efficacy of the BGT at 6 months after 18 
12 
switching from BBT in the patients. Receiver operating characteristic (ROC) curves were 1 
used to calculate the accuracy of the parameters determined significantly as predictive 2 
markers of a good-responder at 6 months after switching from BBT to BGT. Statistical 3 
analysis was carried out using JMP Pro version 11.2 (SAS Institute, Cary, NC, USA). 4 
P-values less than 0.05 were considered significant. 5 
 6 
 7 
3. RESULTS 8 
A total of 49 patients agreed to participate in the study. Among them, 8 9 
participants were excluded: in 4 of these cases type 1 diabetes could not be ruled out 10 
through the detection of positive anti-islet autoantibodies in the serum, and in 4 of them 11 
some portion of the required data, including results of anti-islet autoantibodies or some 12 
results of insulin and glucagon levels during the OGTTs, were not available. We thus 13 
enrolled 41 patients in the study, and all of them were able to continue BGT for more than 14 
6 months of the study period without any adverse events. Among the 41 patients, 28 15 
(68.3%) were classified as good-responders and 13 (31.7%) as poor-responders at 6 16 
months after switching therapy. The baseline characteristics of the patients are shown in 17 
Table 1. The daily dose of basal insulin was significantly lower in good-responders than in 18 
13 
poor-responders. The other baseline parameters, including age, height, weight, body mass 1 
index (BMI), duration of diabetes, duration of insulin treatment prior to the study, duration 2 
of BBT prior to the study, degrees of glycaemic control and diabetic complications, 3 
residual β-cell function estimated by the C-peptide index at fasting and 2h after a 75-g 4 
glucose load, total daily dose of bolus insulin and use of OADs were not significantly 5 
different between good- and poor-responders. There were no significant differences in 6 
three-day means of blood glucose levels at each pre-prandial and bedtime just after 7 
switching from BBT to BGT between good- and poor-responders. (Fig. 2a).  8 
HbA1c levels in good-responders were significantly decreased compared to 9 
baseline as early as 3 months after switching therapy and maintained until 6 months, while 10 
those in poor-responders were significantly increased compared to baseline at 6 months 11 
after switching therapy (Fig. 2b). Severe hypoglycaemia requiring medical treatment was 12 
not observed in any of the participants during the study period even though more than half 13 
(56.1%) of the good-responders achieved HbA1c <7.0% at 6 months after switching 14 
therapy. 15 
Body weights were similarly decreased in both groups after switching therapy 16 
(Fig. 2c). The dosages of liraglutide were increased after switching therapy in both groups 17 
while the dosage needed in good-responders was significantly less than that needed in 18 
14 
poor-responders at 3 months (Fig. 2d). More basal insulin was required in poor-responders 1 
than in good-responders on admission and at 3 and 6 months after switching therapy (Fig. 2 
2e). In some patients, metformin usage was increased during hospitalization, but there 3 
were no significant differences in the use of metformin after discharge in each group (Fig. 4 
2f).  5 
Under baseline conditions during 1st-OGTT, not only plasma glucose but also 6 
insulin/glucagon responses to glucose load were similar between good-responders and 7 
poor-responders (Fig. 3a-d, Supplementary Fig. 1). Under liraglutide administration 8 
during 2nd-OGTT, plasma glucose excursion was significantly decreased compared to that 9 
during 1st-OGTT in both groups (Fig. 3a). The increases in plasma glucose levels from 0 10 
to 120 min (ΔGlucose120min) were significantly suppressed after liraglutide administration 11 
in both groups (Fig. 3e). Insulin responses to glucose load during 2nd-OGTT were 12 
significantly increased compared to those during 1st-OGTT in good-responders but not in 13 
poor-responders (Fig. 3b), although fasting serum insulin concentrations were 14 
significantly elevated just after starting liraglutide in both groups. The changes in the 15 
serum levels of insulin from 0 to 120 min (ΔInsulin120min) during 2nd-OGTT were 16 
significantly increased compared to those during 1st-OGTT in good-responders but not in 17 
poor-responders (Fig. 3f). The data of increased response of serum C-peptide levels during 18 
15 
2nd-OGTT compared to those during 1st-OGTT in good-responders but not in 1 
poor-responders (Fig. 3c, g) were similar to those of serum insulin levels (Fig. 3b, f). 2 
Plasma glucagon concentrations at each time-point of OGTT were not significantly 3 
different between the 1st-OGTT and 2nd-OGTT in either group (Fig. 3d). However, the 4 
suppressions of glucagon secretion from 0 to 120 min (ΔGlucagon120min) during 2nd-OGTT 5 
were significantly larger than those during 1st-OGTT in each group (Fig. 3h).  6 
We also studied the molar ratios of insulin to glucagon and of proinsulin to 7 
insulin in the fasting sera derived from 1st- and 2nd-OGTT samples. Before liraglutide 8 
administration, there were no differences in these ratios between good- and 9 
poor-responders. Interestingly, a significant increase in the fasting insulin/glucagon ratio 10 
and decrease in the fasting proinsulin/insulin ratio 2 days after liraglutide administration 11 
(2nd-OGTT) compared to baseline (1st-OGTT) were observed in good-responders but not 12 
in poor-responders (Fig. 3i, j). 13 
In order to identify predictive factors for good-responders, we performed logistic 14 
regression analyses of clinical characteristics or insulin/glucagon responses obtained from 15 
each of the OGTTs and from the data of the 1st-OGTT subtracted from the data of the 16 
2nd-OGTT (Table 2). No factors were found to be significantly predictive of a good 17 
responder among either clinical characteristics or the results of OGTT before liraglutide 18 
16 
administrations (1st-OGTT). From the subtraction data, only “Increase in ΔInsulin120min,” 1 
which represents the value derived from subtracting ΔInsulin120min in the 1st-OGTT from 2 
that in the 2nd-OGTT, was significantly associated with good glycaemic control at 6 3 
months after switching therapy. The ROC analysis showed that the cut-off value of 4 
“Increase in ΔInsulin120min” to predict a good-responder at 6 months after switching the 5 
therapy was 1.8 μU/mL (area under the curve 0.753; 95% confidence interval 0.537-0.889) 6 
with 93% sensitivity and 62% specificity (Fig. 3k). 7 
 8 
 9 
4. DISCUSSION 10 
Here we found that more than two thirds of type 2 diabetic patients with 11 
decreased insulin secretory capacity who had needed intensive basal-bolus therapy showed 12 
good glycaemic controls when bolus insulin was replaced with liraglutide. It has been 13 
shown that the efficacy of switching injectable therapy from insulin to liraglutide in the 14 
patients with type 2 diabetes depends on the sustained endogenous insulin-secreting 15 
capacity [9, 10, 16, 17]. We previously demonstrated that sulfonylurea use before 16 
liraglutide treatment was associated with poor glycaemic response to mono-injectable 17 
therapy of liraglutide among patients with type 2 diabetes [18]. It has been shown that 18 
17 
patients with diabetes using sulfonylurea have reduced endogenous insulin secretion [19]. 1 
Because most of the patients in our current study had required intensive basal-bolus 2 
insulin therapy to maintain their glucose levels, their baseline capacity of insulin secretion 3 
seemed to be decreased overall, as shown in Fig. 3. Liraglutide might be effective even in 4 
patients with type 2 diabetes with reduced residual β-cell functions when used with basal 5 
insulin, due to the compensation of insulin action. However, not all the patients exhibited 6 
an improvement of glycaemic control upon switching from basal-bolus therapy to 7 
combination therapy with basal insulin/liraglutide. One third of cases exhibited worse 8 
glycaemic control, although the body weights were reduced after switching therapy. It is 9 
clinically important to predict the efficacy of switching therapy in patients with type 2 10 
diabetes. We therefore explored the predictive factors of the efficacy from the point of 11 
view of clinical features, including the responses of β- and α-cells to glucose load, not 12 
only at baseline (1st-OGTT) but also under liraglutide administration (2nd-OGTT). 13 
First, we found no significant differences in baseline parameters except the 14 
dosage of basal insulin between good-responders and poor-responders (Table 1). In 15 
addition, no significant differences in the β- and α-cell functions were observed between 16 
the two groups in the 1st-OGTT (Supplementary Fig. 1). These facts suggest that it is 17 
difficult to predict the long-term glycaemic control after switching therapy. Usui et al. 18 
18 
recently reported that the residual β-cell function indicated as the fasting C-peptide index 1 
> 1.103 was a predictive marker for the achievement of HbA1c <7.0% by combination 2 
therapy with basal insulin and liraglutide at 1 year after switching from therapy with 3 
basal-bolus or basal insulin with OADs [12]. Our data on the baseline C-peptide indexes 4 
and endogenous insulin responses observed in 1st-OGTT in the good-responders were not 5 
significantly different from the data in the poor-responders (Table 1, Supplementary Fig. 6 
1). ROC analysis for baseline C-peptide index to predict a good-responder of our study did 7 
not reach a significant level (Supplementary Fig. 2). If Usui’s value of 1.103 could have 8 
been applied in our study for the cut-off of C-peptide index for the achievement of HbA1c 9 
<7.0% at 6 months after switching therapy, it would have been calculated at 43% for 10 
sensitivity, 78% for specificity, 71% for positive-predictive value, and 52% for 11 
negative-predictive value. Unfortunately, we could not follow up the glycaemic controls of 12 
the participants until 1 year after switching therapy. Furthermore, the participants of 13 
Usui’s study included patients with relatively preserved β-cell function who did not need 14 
bolus insulin prior to enrolling into the study. It is probable that the residual β-cell 15 
functions of our patients were decreased more than those of Usui’s study. The discrepancy 16 
about C-peptide index between Usui’s study and our study might have been caused by 17 
some degree of difference in the study designs and the baseline characteristics of eligible 18 
19 
subjects.  1 
Second, we found that the responses of insulin secretion to oral glucose load were 2 
significantly enhanced just after liraglutide administration (2nd-OGTT) in good-responders 3 
but not in poor-responders. These facts might suggest that liraglutide could improve β-cell 4 
function even in the patients with long-standing disease and minimal baseline capacity of 5 
insulin secretion. Our logistic regression analyses demonstrated that “Increase in 6 
ΔInsulin120min”, which indicates the enhancement of insulin response to glucose load under 7 
liraglutide administration, was the only marker associated with good glycaemic control 8 
after switching therapy (Table 2). Especially, ROC analyses estimated the cut-off value of 9 
“Increase in ΔInsulin120min” to predict good response 6 months after switching therapy was 10 
1.8μU/mL with 84% for positive-predictive value and 73% for negative-predictive value 11 
(Fig. 3k). Although this threshold of “Increase in ΔInsulin120min” could not provide 12 
clinicians with a perfect information to predict the response, these findings suggest that the 13 
dual evaluation of the glucose-dependent insulin responses before and just after liraglutide 14 
administration could be a predictive approach to determine whether liraglutide can replace 15 
bolus insulin in patients who had longstanding basal-bolus therapy. Eventually, it could 16 
avoid a long-term “try and see” prescription pattern. 17 
To investigate the mechanisms of the association between the enhancement of 18 
20 
insulin response under liraglutide administration and glycaemic control 6 months after 1 
switching therapy, we evaluated the fasting ratio of proinsulin/insulin, which is reflected in 2 
the degree of insulin processing and the secretion of more immature insulin granules. 3 
Increases in the ratio are seen in patients with recent-onset type 1 diabetes [20] and those 4 
with type 2 diabetes [21], and are already apparent in the stage of impaired glucose 5 
tolerance [22]. These are generally thought to be the consequence of chronic β-cell 6 
stimulation in conditions with β-cell loss and to reflect a primary reduction of insulin 7 
secretory capacity [23, 24]. In this study, we observed that the fasting proinsulin/insulin 8 
ratio was significantly decreased 2 days after liraglutide administration compared to that 9 
before administration in good-responders but not in poor-responders (Fig. 3j). This might 10 
reflect that the recovery from β-cell exhaustion seen after liraglutide administration was 11 
more remarkable in good-responders than in poor-responders. 12 
Of note, the short-term (2-day) administration of liraglutide improved the glucose 13 
excursion during OGTT in poor-responders without an enhancement of insulin response 14 
(right panel of Fig. 3a, b). A possible mechanism is the effect of GLP-1 on the suppression 15 
of glucagon secretion or that on the delay of gastric emptying. We observed paradoxical 16 
increases in glucagon secretion after ingestion of glucose, or so-called paradoxical 17 
hyperglucagonemia [25], before liraglutide administration in both good- and 18 
21 
poor-responders (left panel of Supplementary Fig. 1d). A mere 2-day administration of 1 
liraglutide improved the paradoxical hyperglucagonemia and the glucagon suppression 2 
during the 120 minutes of OGTT (ΔGlucagon120min) to a comparable degree between the 3 
two groups (right panel of Supplementary Fig. 1d). Logistic regression analyses also 4 
demonstrated that there was no association between the improvement of glucagon 5 
suppression and a good treatment response, as shown in Table 2. These findings suggest 6 
that the improvement of the glucose excursion during OGTT in poor-responders might 7 
have been affected by the effect of GLP-1 on the delaying gastric emptying rather than the 8 
effect of GLP-1 on the suppression of glucagon secretion. It has been shown that the 9 
slowing of gastric emptying by long-acting GLP-1RAs such as liraglutide becomes 10 
attenuated over time, while the effect by short-acting GLP-1RAs is maintained [26]. These 11 
phenomena might be partially associated with the worsening of glycaemic control in the 12 
poor-responders after switching therapy over time (Fig. 2b). 13 
The current study had several limitations. First, the sample size was small 14 
because the study was administered in a single centre. Second, we could not show the 15 
efficacy more than 6 months after switching therapy because we terminated the study at 6 16 
months. Third, we could not evaluate the insulin resistance of the participants on the 17 
baseline. Germain et al. recently reported that the insulin resistance evaluated by insulin 18 
22 
tolerance test was useful to predict the efficacy of mono-injectable therapy with liraglutide 1 
in patients with type 2 diabetes who had been treated with OADs. We did not evaluate the 2 
insulin resistance of the patients by insulin tolerance test. Since we carried out 1st-OGTT 3 
before administration of liraglutide while under basal insulin, metformin and pioglitazone 4 
until the preceding day of the OGTT, the homeostatic model assessment for insulin 5 
resistance [27] and Matsuda index [28] were not able to estimate the baseline insulin 6 
resistance of the patients. Fourth, there was no precise rule for the dose adjustments of 7 
basal insulin by the clinicians, except that the fasting glucose level should be maintained 8 
below a target of 120 mg/dL. In an outpatient setting, especially for the poor-responders, it 9 
might be insufficient to increase the use of basal insulin to maintain lower fasting glucose 10 
levels. It has been demonstrated that the effects of GLP-1 on the secretion of insulin and 11 
glucagon are decreased in patients with poorly controlled fasting glucose levels [29]. The 12 
incretin effect had already declined when the glucose concentrations exceeded the upper 13 
limit of normal. This was thought to be a consequence of a hyperglycaemia-induced 14 
downregulation of GLP-1 receptor expression [30, 31]. Fifth, we could not evaluate 15 
compliance to the diet therapy and exercise education. It might be a bias between 16 
good-responders and poor-responders. Sixth, the maximum dose of liraglutide permitted in 17 
Japan is 0.9 mg per day. Therefore, our approach would not be sufficient for patients in 18 
23 
other countries where liraglutide of up to 1.8 mg per day has been approved. 1 
In summary, we demonstrated that liraglutide can replace bolus insulin in more 2 
than two thirds of Japanese patients with type 2 diabetes with reduced β-cell function who 3 
have required longstanding basal-bolus insulin. Before switching to the combination of 4 
basal insulin/liraglutide, it may be hard to predict the long-term glycaemic responses of 5 
the combination therapy, even if the baseline β- and α-cell functions are evaluated 6 
precisely. However, dual evaluation of the insulin responses to glucose load before and 7 
just after liraglutide administration could be valuable to predict long-term glycaemic 8 
control when replacing bolus insulin with liraglutide in patients treated with longstanding 9 
basal-bolus insulin. 10 
 11 
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 20 
 21 
FIGURE LEGENDS 22 
Figure 1. The study design.  23 
(a) A 75-g OGTT was performed before (1st-OGTT) and 2 days after starting liraglutide 24 
(2nd-OGTT) to evaluate the glucose-dependent responses of β- and α-cells by the GLP-1 25 
28 
stimulation. *The maximum dose of liraglutide permitted in Japan is 0.9 mg per day. 1 
(b) Blood samplings were performed at fasting (0 min), and 30, 60, 120 min after 2 
ingestion of glucose in each OGTT. Liraglutide was injected 30 minutes prior to starting 3 
the 2nd-OGTT. Basal insulin and oral anti-diabetic agents including metformin and 4 
pioglitazone were held until the preceding day in each OGTT. 5 
 6 
Figure 2. Comparisons of the outcomes and treatments between good-responders 7 
(n=28) and poor-responders (n=13).  8 
(a) Three-day means of blood glucose levels just before discharge from the hospital in 9 
good-responders (white bar) vs. poor-responders (slashed bar). BB, before breakfast; BL, 10 
before lunch; BD, before dinner; BT, bed time. (b) HbA1c levels. (c) Weight changes. (d) 11 
Dose of liraglutide. (e) Dose of basal insulin. (f) Dose of metformin. The circles and 12 
squares indicate good-responders and poor-responders, respectively. The opened or closed 13 
symbols indicate before or after liraglutide administration, respectively. Adm, admission; 14 
Dis, discharge; -3M, -3 months; 0M, 0 month; 3M, 3 months; 6M, 6 months. The bar 15 
indicates the S.D. *p<0.05 vs. 0M (Dis) in good-responders and poor-responders; †p<0.05 16 
for good- vs. poor-responders at each time-point using repeated-measures analysis of 17 
variance. 18 
29 
 1 
Figure 3. Results of 75-g OGTTs before (1st-) and 2 days after (2nd-) starting 2 
liraglutide on good-responders (GR, n=28) and poor-responders (PR, n=13).  3 
Panels (a)-(d) show the comparison of the concentrations of plasma glucose, serum insulin, 4 
serum C-peptide and plasma glucagon between before (opened symbols, 1st-OGTT) and 2 5 
days after starting liraglutide (closed symbols, 2nd-OGTT) in good-responders (circle 6 
symbols, left panels) and poor-responders (square symbols, right panels), respectively.  7 
Panels (e)-(h) show the comparison of the values of the changes from baseline (0 min) to 8 
120 min during the OGTTs in the levels of glucose, insulin, C-peptide and glucagon, 9 
indicated as ΔGlucose120min, ΔInsulin120min, ΔC-peptide120min and ΔGlucagon120min, between 10 
before (white bars, 1st-OGTT) and 2 days after starting liraglutide (black bars, 2nd-OGTT). 11 
Panels (i) and (j) show the comparisons of the molar ratio of insulin to glucagon and that 12 
of proinsulin to insulin in the fasting sera between before (white bars, 1st-OGTT) and 2 13 
days after starting liraglutide (black bars, 2nd-OGTT). GR, good-responders; PR, 14 
poor-responders. The bar indicates the S.D. *p<0.05 for 1st- vs. 2nd-OGTT in each group 15 
by paired t-test. †p<0.05 for good- vs. poor-responders at each time-point by t-test. Panel 16 
(k) show the receiver operating characteristic (ROC) curves of “the subtraction of 17 
ΔInsulin120min during 1st-OGTT from ΔInsulin120min during 2nd-OGTT”, i.e. “Increase in 18 
30 
ΔInsulin120min”, for the good-responder at 6 months after switching the therapy. AUC, area 1 
under the curve; CI, confidence interval; PPV, positive-predictive value; NPV, 2 
negative-predictive value. 3 
 4 
 5 
APPENDIX 6 
Supplementary Figure 1.  7 
Modified results of Figure 3(a)-(d), that is, the comparison between good-responders 8 
and poor-responders in 75-g OGTTs before (1st-) and 2 days after (2nd-) starting 9 
liraglutide.  10 
Panels (a)-(d) show the comparison of the concentrations of plasma glucose, serum insulin, 11 
serum C-peptide and plasma glucagon between good-responders (circle symbols) and 12 
poor-responders (square symbols) in 1st-OGTT (opened symbols, left panels) and 13 
2nd-OGTT (closed symbols, right panels). The bar indicates the S.D. †p<0.05 for good- vs. 14 
poor-responders at each time-point by t-test. 15 
 16 
 17 
Supplementary Figure 2.  18 
ROC analysis of the baseline C-peptide index at fasting for a good-responder, which did 19 
not reach a significant level. 20 
Table 1. Baseline features of participants 
 Total Good
responders
Poor 
responders  
P-value 
 
n 41 28 13  
Gender (Male:Female) 21:20 15:13 6:7 0.92 
Age (years) 62.9 ± 11.0 64.4 ± 8.1 59.8 ± 15.1 0.39 
Duration of diabetes (years) 
Duration of insulin therapy (years) 
Duration of BBT (years) 
Height (cm) 
Weight (kg) 
BMI (kg/m2) 
HbA1c (NGSP, %) 
eGFR (mL/min/1.73m2) 
C-peptide index at fasting 
C-peptide index at 2h during OGTT 
Proteinuria (g/gCr) 
Retinopathy (n, %) 
Neuropathy (n, %) 
Cardiovascular disease (n, %) 
 
Pharmacological treatment 
Total insulin (units/day) 
   Basal insulin (units/day) 
    Bolus insulin (units/day) 
   Metformin (n, %) 
   Sulfonylurea (n, %) 
   Glinide (n, %) 
DPP4 inhibitor (n, %) 
Pioglitazone (n, %) 
α-GI (n, %) 
    SGLT2 inhibitor (n, %) 
 
21.2 ± 8.8
11.3 ± 7.3
8.6 ± 4.6
160.8 ± 8.1 
76.3 ± 19.3
29.4 ± 6.7
7.6 ± 1.1
61.4 ± 18.6 
0.96 ± 0.55  
1.68 ± 1.22
0.58 ± 1.22 
25 (61.0)
27 (65.9)
15 (36.6)
47.5 ± 20.8
18.9 ± 8.7
28.7 ± 15.6
22 (53.7)
0 (0.0)
1 (2.4)
12 (29.3)
5 (12.2)
3 (7.3)
2 (4.9)
 
20.5 ± 8.0
10.6 ± 7.3
8.0 ± 4.0
161.1 ± 6.8
73.9 ± 13.8
28.5 ± 5.3
7.6 ± 1.2
61.1 ± 17.9 
1.01 ± 0.51
1.69 ± 1.02
0.46 ± 1.11 
16 (57.1)
17 (60.7)
9 (32.1)
43.3 ± 17.7
17.1 ± 8.4
26.2 ± 12.6
14 (50.0)
0 (0.0)
1 (3.6)
6 (21.4)
3 (10.7)
2 (7.1)
1 (3.6)
 
22.9 ± 10.2 
12.9 ± 7.1 
9.7 ± 5.6 
160.3 ± 10.4 
81.3 ± 26.9 
31.3 ± 8.7 
7.8 ± 1.1 
62.0 ± 19.8 
0.86 ± 0.60 
1.66 ± 1.66 
0.83 ± 1.39 
9 (69.2) 
10 (76.9) 
6 (46.2) 
 
 
56.8 ± 23.8 
22.9 ± 7.8 
33.9 ± 19.6 
8 (61.5) 
0 (0.0) 
0 (0.0) 
6 (46.1) 
2 (15.4) 
1 (7.7) 
1 (7.7) 
 
0.48 
0.26 
0.46 
0.81 
0.41 
0.27 
0.54 
0.94 
0.10 
0.46 
0.33 
0.51 
0.48 
0.49 
 
 
0.055 
0.028 
0.18 
0.52 
---- 
1.00 
0.15 
0.64 
1.00 
0.54 
 
 BBT, basal-bolus insulin therapy; BMI, body mass index; eGFR, estimated glomerular filtration rate; 
C-peptide index, 100 × C-peptide (ng/mL)/glucose (mg/dL); OGTT, 75-g oral glucose tolerance test; DPP4, 
dipeptidyl peptidase-4; α-GI, α-glucosidase inhibitor; SGLT2, sodium-glucose cotransporter 2. The values 
are given as the means±standard deviations. P-values for differences between good- and poor-responders 
were calculated using the t-test or Chi-square test. 
 
 
Table 2. Logistic regression analyses of clinical characteristics or insulin/glucagon responses derived from 
OGTTs to predict good-responders at 6 months after switching from basal-bolus insulin to basal 
insulin/liraglutide combination therapy. 
 
Predictors of good-responder Univariate Multivariate 
 OR (95% CI) P-value OR (95% CI) P-value
Age (per 1 year) 1.04 (0.98-1.10) 0.21 
0.66 
0.21 
0.053 
0.29 
0.003 
0.61 
1.00 (0.90-1.10) 0.95 
0.13 
0.55 
0.32 
0.22 
0.018 
0.76 
Sex (Male) 1.35 (0.36-5.04) 4.52 (0.58-35.37) 
BMI (per 1 kg/m2) 0.94 (0.85-1.04) 1.06 (0.87-1.28) 
Total insulin dose (per 1 unit/day) 
Duration of BBT (per 1 year) 
Increase in ΔInsulin120min (per 1 μU/mL) 
Decrease in ΔGlucagon120min (per -1 pg/mL) 
0.97 (0.93-1.01)
0.93 (0.80-1.07)
1.07 (1.01-1.14)
1.01 (0.97-1.05) 
0.97 (0.91-1.03) 
0.89 (0.72-1.09) 
1.09 (1.01-1.17) 
1.01 (0.97-1.06) 
BMI, body mass index; BBT, basal-bolus insulin therapy; OR, odds ratio; CI, confidence interval. “Total insulin 
dose” indicates the total daily dose of insulin needed just before switching therapy. ΔInsulin120min and 
ΔGlucagon120min mean the changes in the levels of insulin and glucagon from baseline (0 min) to 120 min during 
OGTT, respectively. “Increase in ΔInsulin120min” and “Decrease in ΔGlucagon120min” were calculated as follows. 
“Increase in ΔInsulin120min” = (ΔInsulin120min during 2nd-OGTT) – (ΔInsulin120min during 1st-OGTT); “Decrease in 
ΔGlucagon120min” = (ΔGlucagon120min during 2nd-OGTT) – (ΔGlucagon120min during 1st-OGTT). 
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